FDA accepts to review BMS’ resubmitted NDA for daclatasvir to treat HCV genotype 3
The company said that the original NDA has been amended to include data from the Phase III ALLY-3 trial, which tested a 12-week, ribavirin-free regimen and resulted in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.